RenovoRx CEO to Highlight Q1 Revenue Growth and Clinical Trial Progress at Investment Conference
Event summary
- RenovoRx CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23, 2026.
- RenovoRx reported record Q1 2026 revenue of $563,000, driven by growing demand for RenovoCath.
- The company expects to complete enrollment in its Phase III TIGeR-PaC clinical trial by the end of June 2026.
- RenovoRx recently received FDA Orphan Drug Designation for oxaliplatin in pancreatic cancer, its third overall.
The big picture
RenovoRx's presentation comes at a critical juncture as it balances commercializing its FDA-cleared RenovoCath device with advancing its clinical pipeline. The company's focus on targeted oncology therapies aligns with broader industry trends toward precision medicine, particularly in high-unmet-need areas like pancreatic cancer. With record Q1 revenue and strategic regulatory designations, RenovoRx is positioning itself for potential inflection points in both revenue growth and clinical validation.
What we're watching
- Revenue Trajectory
- Whether RenovoRx can sustain its accelerating adoption of RenovoCath at high-volume cancer centers.
- Clinical Milestones
- The pace at which the TIGeR-PaC trial progresses toward final data readout in mid-to-late 2027.
- Regulatory Strategy
- How RenovoRx leverages its Orphan Drug Designations to secure market exclusivity and expedite approvals.
Related topics